Is A CURE ON the WAY? – THE BAD MEDICINE OF GENERICS, CITIZEN PETITIONS, AND NOERR-PENNINGTON IMMUNITY

Show full item record

Title: Is A CURE ON the WAY? – THE BAD MEDICINE OF GENERICS, CITIZEN PETITIONS, AND NOERR-PENNINGTON IMMUNITY
Author: Lee, Stacey
Abstract: Over the next five years, approximately 110 drugs, including blockbuster products such as Sanofi-Aventis’ allergy medicine Flomax, GlaxoSmithKline’s herpes medication Valtrex, and Pfizer’s cholesterol medication Lipitor will lose their patent protection. In 2009 alone, brand-name drugs coming off patent were valued at more than 10.8 billion dollars. As market exclusivity for these drugs ends, the doors for generic production will open. Generic drugs generally enter the market priced 20 to 80 percent lower than their branded counterparts, and generics can capture 44 to 80 percent of brand-name drug sales within a year after release. This price competition from generic drugs threatens the profits of brand-name manufacturers and reduces their returns on innovative activity. As a result, some brand-name drug manufacturers have resorted to aggressive tactics to blunt the impact of competition.
URI: http://jhir.library.jhu.edu/handle/1774.2/34009
Date: 2010-03
Subject: K2
Citizen Petitions
Sham
Noerr-Pennington
Generics
Series: The Johns Hopkins Carey Business School Working Paper Series;2010-03-001

Files in this item

Files Size Format Download
SBLee Generics Noerr-Pennington Sham.pdf 380.7Kb application/pdf Download

The following license files are associated with this item:

This item appears in the following Collection(s)

Show full item record